Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

Abstract:

:Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent with the known hepatobiliary excretion of AD 32 and metabolites. Significant accumulations of radioactivity and fluorescence were found in kidney, spleen, large intestine (including contents), lung, and heart. Lesser levels were found in muscle and fat. Little radioactivity and fluorescence were found in brain. Liquid chromatographic analysis of extracts of small intestine and liver homogenates showed N-trifluoroacetyladriamycin (AD 41) as the major fluorescent species, and also revealed N-trifluoroacetyladriamycinol (AD 92) and occasional low levels of AD 32. In addition, there was a major peak of nonfluorescent radioactive material and two fluorescent nonradioactive signals (unknowns 1 and 2), indicative of cleavage of the radiolabel from the chromophore.

authors

Israel M,Karkowsky AM,Khetarpal VK

doi

10.1007/BF00253006

subject

Has Abstract

pub_date

1981-01-01 00:00:00

pages

25-30

issue

1

eissn

0344-5704

issn

1432-0843

journal_volume

6

pub_type

杂志文章
  • Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.

    abstract:PURPOSE:Based on the results of first-line chemotherapy for advanced pancreatic cancer, S-1 was confirmed to be non-inferior to gemcitabine. However, the recommended regimen of 4 weeks of administration followed by 2 weeks of drug withdrawal frequently causes adverse effects. On the other hand, we experienced in clinic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-013-2323-6

    authors: Yamaue H,Satoi S,Kanbe T,Miyazawa M,Tani M,Kawai M,Hirono S,Okada K,Yanagimoto H,Kwon AH,Mukouyama T,Tsunoda H,Chijiiwa K,Ohuchida J,Kato J,Ueda K,Yamaguchi T,Egawa S,Hayashi K,Shirasaka T

    更新日期:2014-01-01 00:00:00

  • Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential.

    abstract:BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1453-3

    authors: Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

    更新日期:2011-07-01 00:00:00

  • Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.

    abstract:BACKGROUND:In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4-dihydroxypyridine components of S-1 and examined correlati...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1795-5

    authors: Wada M,Yamamoto M,Ryuge S,Nagashima Y,Hayashi N,Maki S,Otani S,Katono K,Takakura A,Yanaihara T,Igawa S,Yokoba M,Mitsufuji H,Kubota M,Katagiri M,Masuda N

    更新日期:2012-04-01 00:00:00

  • Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.

    abstract:PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800000260

    authors: Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

    更新日期:2001-05-01 00:00:00

  • Changes in serum iron levels following very high-dose cisplatin.

    abstract::A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they rea...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00252983

    authors: Pollera CF,Ameglio F,Reina S,Nardi M,Abbolito MR,Parracino C

    更新日期:1987-01-01 00:00:00

  • Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.

    abstract::Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2926-1

    authors: Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

    更新日期:2016-02-01 00:00:00

  • Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents.

    abstract::The 9L gliosarcoma growing subcutaneously in the hind leg of the Fisher 344 rat contains major areas of severe (< 5 mmHg) hypoxia, making up about 49% of the tumor. Intravenous administration of an ultrapurified polymerized bovine hemoglobin solution (8 ml/kg) along with normal air breathing reduces the percentage of ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686024

    authors: Teicher BA,Holden SA,Menon K,Hopkins RE,Gawryl MS

    更新日期:1993-01-01 00:00:00

  • Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

    abstract:PURPOSE:Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS:Patients received ramucir...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00280-018-3560-5

    authors: Smit EF,Garon EB,Reck M,Cappuzzo F,Bidoli P,Cohen RB,Gao L,O'Brien LM,Lee P,Zimmermann A,Ferry DR,Melemed AS,Pérol M

    更新日期:2018-07-01 00:00:00

  • Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.

    abstract:PURPOSE:In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated. METHODS:Patients with hepatocellular carcinoma no longer amenable to established forms o...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-001-0400-8

    authors: Ueno H,Okada S,Okusaka T,Ikeda M,Kuriyama H

    更新日期:2002-02-01 00:00:00

  • Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

    abstract::We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its m...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686174

    authors: van Tellingen O,Beijnen JH,Nooijen WJ,Bult A

    更新日期:1993-01-01 00:00:00

  • Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.

    abstract:PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3625-5

    authors: Thomas F,Veal GJ,El Balkhi S,Lafont T,Picard N,Brugières L,Chatelut E,Piguet C

    更新日期:2018-08-01 00:00:00

  • Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.

    abstract:PURPOSE:This study was designed to evaluate the anti-tumor activity and toxicity profile of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma (NPC) who had been pretreated with platinum-based chemotherapy. METHOD:This is an open label, single arm phase II trial. All patients were treated ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0441-8

    authors: Zhang L,Zhang Y,Huang PY,Xu F,Peng PJ,Guan ZZ

    更新日期:2008-01-01 00:00:00

  • A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.

    abstract:PURPOSE:This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). METHODS:Patients with advanced solid malignancies received mFOLFOX6 in 2-week cycles with escalating sunitinib doses (2...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-1880-4

    authors: Leong S,Eckhardt SG,Chan E,Messersmith WA,Spratlin J,Camidge DR,Diab S,Khosravan R,Lin X,Chow Maneval E,Lockhart AC

    更新日期:2012-07-01 00:00:00

  • Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.

    abstract:PURPOSE:Streptozocin (STZ) is a key agent for treating advanced pancreatic neuroendocrine tumors (pNET). Most STZ regimens for pNET are daily and also include 5-fluorouracil (5FU), whereas STZ monotherapy and weekly regimens have also been applied in daily practice in Japan. The present study aimed to evaluate response...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-018-3656-y

    authors: Shibuya H,Hijioka S,Sakamoto Y,Ito T,Ueda K,Komoto I,Kobayashi N,Kudo A,Yasuda H,Miyake H,Arita J,Kiritani S,Ikeda M,Imaoka H,Ueno M,Kobayashi S,Furuta M,Nagashio Y,Murohisa G,Aoki T,Matsumoto S,Motoya M,Azemo

    更新日期:2018-10-01 00:00:00

  • MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.

    abstract:BACKGROUND:The recurrence rate of hepatocellular carcinoma (HCC) after partial hepatectomy is still high. How to choose the most appropriate anti-tumor drug in the early postoperative period is crucial to improve the prognosis of patients. Recently, MiniPDX has been widely used as a new and reliable preclinical researc...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-020-04182-1

    authors: Yang L,Yuan Z,Zhang Y,Cui Z,Li Y,Hou J,Liu X,Liu Z,Shi R,Tian Q,Wang J,Wang L

    更新日期:2021-01-01 00:00:00

  • In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.

    abstract::Brain microdialysis was applied to sample free methotrexate (MTX) concentrations in brain extracellular fluid of normal and RG-2 glioma-bearing rats. All animals received 50 mg/kg of MTX intra-arterially following which serial blood and interstitial fluid samples were collected for 3 h and measured for MTX by an HPLC ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050518

    authors: Devineni D,Klein-Szanto A,Gallo JM

    更新日期:1996-01-01 00:00:00

  • Dosing algorithm revisit for busulfan following IV infusion.

    abstract:PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2660-0

    authors: Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

    更新日期:2015-03-01 00:00:00

  • Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

    abstract:PURPOSE:Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial distribution of drugs within that tissue. Here, we compare the time-dependent spatial distribution of three anticancer drugs within tumors, heart, kidney, l...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-013-2176-z

    authors: Patel KJ,Trédan O,Tannock IF

    更新日期:2013-07-01 00:00:00

  • Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.

    abstract:PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050854

    authors: de Vos D,Slee PH,Briggs RJ,Stevenson D

    更新日期:1998-01-01 00:00:00

  • A phase II study of temozolomide in hormone-refractory prostate cancer.

    abstract:INTRODUCTION:Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been demonstrated. Based on t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002800051027

    authors: van Brussel JP,Busstra MB,Lang MS,Catsburg T,Schröder FH,Mickisch GH

    更新日期:2000-01-01 00:00:00

  • Autophagy in cancer stem/progenitor cells.

    abstract::Macroautophagy is widely accepted as a cytoprotective mechanism against various environmental stresses. While inhibition of autophagy is generally considered to increase the susceptibility of cancer cells to therapeutic agents, whether it also plays a similar role in tumor stem cells is unclear and still controversial...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-014-2634-2

    authors: Lin YH,Huang YC,Chen LH,Chu PM

    更新日期:2015-05-01 00:00:00

  • Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).

    abstract::Forty-one previously treated patients with advanced Hodgkin's disease were treated with a combination chemotherapy regimen -- ABVD (adriamycin, bleomycin, velbe/vincristine, imidazole carboxamide). Complete remission was achieved in three patients (7%), partial remission in 23 (56%), and no response in 15 patients (37...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258297

    authors: Sutcliffe SB,Wrigley PF,Stansfeld AG,Malpas JS

    更新日期:1979-01-01 00:00:00

  • A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.

    abstract:PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2760-5

    authors: Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

    更新日期:2015-09-01 00:00:00

  • Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.

    abstract::We evaluated the antiproliferative and the proapoptotic ability of gemcitabine in three non-small-cell lung cancer (NSCLC) cell lines. NCI-H292 (mucoepidermoid carcinoma), NCI-CorL23 (large-cell carcinoma) and NCI-Colo699 (adenocarcinoma) cells were cultured with and without 0.5, 0.05 and 0.005 microM gemcitabine for ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800000183

    authors: Pace E,Melis M,Siena L,Bucchieri F,Vignola AM,Profita M,Gjomarkaj M,Bonsignore G

    更新日期:2000-01-01 00:00:00

  • Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.

    abstract:PURPOSE:Although oral fluoropyrimidine prodrugs are increasingly being administered in preference to intravenous nucleoside analogues in cancer chemotherapy, their activation in malignant liver tissue may be insufficient. OGT 719 (1-galactopyranosyl-5-fluorouracil) is a novel nucleoside analogue, preferentially localiz...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800100332

    authors: Sharma RA,Eatock MM,Twelves CJ,Brown G,McLelland HR,Clayton KT,O'Byrne KJ,Moyses C,Carmichael J,Steward WP

    更新日期:2001-09-01 00:00:00

  • Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.

    abstract::Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and ce...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686835

    authors: Bogush T,Smirnova G,Shubina I,Syrkin A,Robert J

    更新日期:1995-01-01 00:00:00

  • Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.

    abstract:PURPOSE:Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurre...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-013-2086-0

    authors: Shigeyasu K,Kagawa S,Uno F,Nishizaki M,Kishimoto H,Gochi A,Kimura T,Takahata T,Nonaka Y,Ninomiya M,Fujiwara T

    更新日期:2013-04-01 00:00:00

  • A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.

    abstract:PURPOSE:To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS:Patients who failed prior standard therapy o...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1346-5

    authors: Holen KD,Belani CP,Wilding G,Ramalingam S,Volkman JL,Ramanathan RK,Vasist LS,Bowen CJ,Hodge JP,Dar MM,Ho PT

    更新日期:2011-02-01 00:00:00

  • Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.

    abstract:PURPOSE:Multi-drug resistance and cumulative cardiotoxicity are major limitations for the clinical use of anthracyclines. Here, we evaluated and compared the cross-resistance of amrubicin, a third-generation synthetic anthracycline and potent topoisomerase (topo)-II inhibitor with little or no observed cardiotoxicity t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1782-x

    authors: Mamidipudi V,Shi T,Brady H,Surapaneni S,Chopra R,Aukerman SL,Heise C,Sung V

    更新日期:2012-04-01 00:00:00

  • Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

    abstract:PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0370-y

    authors: Katori H,Tsukuda M,Watai K

    更新日期:2007-08-01 00:00:00